Graybug Vision Inc (GRAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRAY Stock Price Chart Interactive Chart >
GRAY Price/Volume Stats
| Current price | $0.90 | 52-week high | $7.06 |
| Prev. close | $0.85 | 52-week low | $0.72 |
| Day low | $0.83 | Volume | 50,668 |
| Day high | $0.95 | Avg. volume | 60,733 |
| 50-day MA | $1.07 | Dividend yield | N/A |
| 200-day MA | $2.15 | Market Cap | 19.28M |
Graybug Vision Inc (GRAY) Company Bio
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.
Latest GRAY News From Around the Web
Below are the latest news stories about Graybug Vision Inc that investors may wish to consider to help them evaluate GRAY as an investment opportunity.
Graybug to Participate in Three Upcoming Medical and Investor ConferencesBALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medical and investor conferences: Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition – Veeral Sheth, MD, to present on “Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age- |
Graybug Vision Makes Key Hires to Further Build Momentum Behind its PipelineBALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will enhance Graybug’s Research & Development (R&D), Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022. “We are at a critical stage in our eff |
Graybug Vision (GRAY) Receives a Hold from Leerink PartnersLeerink Partners analyst Marc Goodman maintained a Hold rating on Graybug Vision (GRAY – Research Report) on December 17 and set a price target of $5.00. The company's shares closed last Wednesday at $2.06, close to its 52-week low of $1.79. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals. Graybug Vision has an analyst consensus of Hold, with a price target consensus of $4.00, which is a 99.0% upside from current levels. |
We Think Graybug Vision (NASDAQ:GRAY) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Graybug Vision, Inc. (NASDAQ:GRAY) Stake Trimmed by Geode Capital Management LLCGeode Capital Management LLC cut its holdings in shares of Graybug Vision, Inc. (NASDAQ:GRAY) by 43.0% in the second quarter, HoldingsChannel reports. The fund owned 70,382 shares of the companys stock after selling 52,989 shares during the quarter. Geode Capital Management LLCs holdings in Graybug Vision were worth $382,000 as of its most recent SEC [] |
GRAY Price Returns
| 1-mo | -16.67% |
| 3-mo | -29.69% |
| 6-mo | -66.67% |
| 1-year | -76.62% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -50.82% |
| 2021 | -93.69% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...